evidence table
Peppermint Oil Irritable Bowel Syndrome Randomized Trial Evidence Table
Structured evidence table for Peppermint Oil Irritable Bowel Syndrome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | Evidence from recent systematic reviews and meta-analyses consistently indicates that peppermint oil is the most effective botanical agent, particularly for reducing abdominal pain and overall IBS symptom severity. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | The aim of this review is to summarize, compare, and critically evaluate all plant extracts studied for the prevention and treatment of IBS, integrating mechanistic pathways, clinical evidence, and current international guideline recommendations to clarify their therapeutic relevance for clinical practice. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | Irritable Bowel Syndrome (IBS) affects 4-15% of the global population, and the limited efficacy of existing pharmacologic therapies has driven growing interest in plant-based therapeutic options among both patients and clinicians. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | A comprehensive assessment of all plant extracts investigated in IBS is therefore essential, given the limited effectiveness of conventional treatments and the increasing interest in complementary approaches. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | Conclusions Positive diagnosis of IBS-D and an evidence-based, symptom-targeted therapeutic approach are recommended to minimize disease burden. | 4 | Ladewski AM (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | Background Given their emphasis on holistic, patient-centered care, nurse practitioners (NPs) and physician assistants (PAs) play an increasingly critical role in the care of patients with gastrointestinal conditions, including irritable bowel syndrome (IBS). | 4 | Ladewski AM (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations. |
| Peppermint Oil Irritable Bowel Syndrome Randomized Trial | Objectives To review key clinical considerations for the diagnosis and management of IBS, focusing on IBS with diarrhea (IBS-D), alongside 2 case presentations. | 4 | Ladewski AM (2026) | Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations. |
Source documents